genie logo

After weeks of previews and early offers, the Black Friday deals are finally in full swing. That means it's one of the best times of the year to upgrade your phone. And if you're looking to get your hands on a sleek Apple iPhone , there are tons of deals out there that can help you get your hands on one for less. Whether you're in the market for the flashy iPhone 16 Pro Max or the budget-friendly iPhone SE , you'll find some incredible savings in our roundup of the season's best savings below. Just be sure to read the fine print closely. Buying a new iPhone on Black Friday isn't always as straightforward as making some other big-ticket purchases, like TVs or laptops . Many Black Friday phone deals require you to meet certain conditions, such as trading in an older device, opening a new line or paying through a monthly installment plan. These deals can be worthwhile if you meet the criteria, with some carriers essentially offering iPhones for free under the right conditions. To help you make the most of these savings, we've rounded up the best deals out there on both current and previous-gen iPhones below. iPhone 16 Black Friday deals Apple isn't known for offering direct discounts very often, but you can still save up to $650 with an eligible trade-in at Apple. That includes devices from Apple, Samsung, Google and others. You'll want to trade in a member of the iPhone 15 series to get the best discount. Walmart is offering up to $1,100 off when you buy an iPhone 16 Pro and up to $930 off the iPhone 16 with an eligible trade-in or activation of a new line of service on a qualifying plan. Final prices will differ depending on which model you choose, as well as which carrier you opt for. More iPhone 16 deals iPhone SE (2022) Black Friday deals Apple is also offering up to $650 off the budget-friendly iPhone SE with an eligible trade-in. With a $429 starting price, that means you could get your hands on this model for free. If your trade-in value exceeds the cost, you'll get the remaining balance back in the form of an Apple gift card. Buy an iPhone SE at full retail price and move your number over to Metro's unlimited plan and you'll get $430 off, making the phone absolutely free. If you don't have an existing number to switch over, you can still save $150 with a new line on a Metro Flex Plus plan. Note : Because Metro is owned by T-Mobile, this offer isn't available to those switching their number from an existing T-Mobile plan. More iPhone SE (2022) deals Previous-gen iPhone Black Friday deals You can buy an iPhone 15 from Verizon today and save up to $1,100 when you activate a new line of service on an Unlimited Welcome, Plus or Ultimate plan, making your new handset completely free. It's getting pretty tough to find the iPhone 14 in stock, but Verizon still has this 2022 Apple phone available and you can get your hands on one for free right now. The carrier is offering up to $730 off the iPhone 14 and 14 Plus when you activate a new line on an Unlimited Welcome, Plus or Ultimate plan. The savings are distributed as bill credits over 36 months. More previous-gen iPhone deals Which iPhone is best? There are quite a few different iPhones on the shelf right now, which can make choosing the right one a little overwhelming. The iPhone 15 is still a great model and the iPhone 16 is our top pick for most people. However, if you need something with some serious hardware, you'll probably want to upgrade to the iPhone 16 Pro or Pro Max . Those on a budget will probably want to grab the third-gen iPhone SE , which normally starts at just $429. However, if you have specific priorities, like a big screen or an advanced camera system, you may want to opt for a high-end model from an older generation, like the iPhone 15 Pro Max , which will help you save some cash without sacrificing too much by way of performance. Where is the best place to buy an iPhone on Black Friday? Deciding whether you should purchase your new Apple phone through a retailer or directly from your carrier will depend on your situation. If you're creating a new line or account, you'll probably want to purchase your iPhone through a major carrier like AT&T, Verizon or T-Mobile , where you can score hundreds in savings -- though you'll be locked into a multiyear contract. If you'd rather not get locked into a service plan, you'll probably want to opt for a prepaid deal from a retailer like Walmart . You'll have to pay for everything upfront, but you will also be free to cancel service at any time. And if you'd rather skip the headache of choosing a service plan altogether, you can pick up an unlocked model from Apple or places like Best Buy , which are both offering some solid Apple Black Friday deals right now.genie logo 。

As Liverpool counts its blessings and looks ahead to a future filled with new opportunities, the club's astute decision-making and strategic prowess shine brightly. While the player in question may have faltered in his later years, Liverpool can move forward knowing that they have emerged from the situation in a position of strength and financial stability.

The decision not to include a buy-back option in the deal can be seen as a calculated move by Inter Milan to prioritize the player's growth and progression at a club where he is thriving. It also indicates Inter's confidence in their ability to produce top talent and their commitment to fostering relationships with other clubs in the footballing world.GSA Capital Partners LLP bought a new position in Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA – Free Report ) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,729 shares of the company’s stock, valued at approximately $268,000. Several other hedge funds and other institutional investors also recently modified their holdings of KNSA. CWM LLC boosted its stake in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals during the first quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after purchasing an additional 3,076 shares in the last quarter. Institutional investors own 53.95% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts recently commented on the company. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $36.60. Insider Activity In related news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 53.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 112,692 shares of company stock worth $2,950,315 in the last three months. Company insiders own 54.57% of the company’s stock. Kiniksa Pharmaceuticals Trading Up 0.9 % Shares of KNSA opened at $21.28 on Friday. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -152.00 and a beta of 0.35. The business’s fifty day simple moving average is $24.29 and its two-hundred day simple moving average is $22.88. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $15.52 and a 12 month high of $28.15. Kiniksa Pharmaceuticals ( NASDAQ:KNSA – Get Free Report ) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. As a group, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year. About Kiniksa Pharmaceuticals ( Free Report ) Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. See Also Five stocks we like better than Kiniksa Pharmaceuticals Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness Vertiv’s Cool Tech Makes Its Stock Red-Hot Golden Cross Stocks: Pattern, Examples and Charts MarketBeat Week in Review – 11/18 – 11/22 What is the S&P/TSX Index? 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

Hospitality VAT reduction is quick fix but can’t be only solution, says top hotelier as industry facing ‘difficult time’One of the defining characteristics of Irving's game is his ability to rise to the occasion when the pressure is at its peak. In clutch moments, when the game is on the line and every move counts, Irving thrives. His confidence and composure under pressure have earned him the reputation of being a clutch performer and a true leader on the court.

As the sun sets on another day, Booker takes a deep breath and resolves to begin again. With determination in his heart and a renewed sense of purpose, he sets his sights on the horizon, ready to rise from the ashes of his past and soar once more. For the fall of Booker may have been swift and hard, but his rise will be even more magnificent. And this time, nothing will stand in his way.Furthermore, Waterdrop Credit recommended that the man take additional precautions to safeguard his personal information and prevent further misuse. This includes regularly monitoring his credit reports for any suspicious activity, using strong and unique passwords for financial accounts, and being cautious about sharing personal information online or over the phone.In addition to government support, market fundamentals have also played a crucial role in stabilizing the property market. With interest rates at historic lows and economic indicators pointing towards recovery, buyers are increasingly confident in their investment decisions. This renewed interest has led to an uptick in sales and transactions, breathing new life into a previously sluggish market.